Core Viewpoint - Baipusais (301080.SZ) plans to issue H-shares and list on the Hong Kong Stock Exchange to further promote its internationalization strategy [1] Company Overview - Baipusais focuses on the biotechnology sector, primarily engaged in the research, production, and sales of biopharmaceuticals, aiming to provide high-quality biological products and services for the healthcare industry [3] - The company is involved in innovative applications of biotechnology, with its main products and services targeting early drug discovery and validation, drug screening and optimization, diagnostic reagent development, preclinical and clinical trials, and process control in drug production [3] Financial Performance - For the first three quarters of 2025, Baipusais reported a revenue of 613 million yuan, representing a year-on-year increase of 32.3% [3] - The net profit attributable to the parent company was 132 million yuan, up 58.6% year-on-year, while the net profit excluding non-recurring items was 133 million yuan, reflecting a 58.8% increase [3] - The net operating cash flow reached 177 million yuan, showing a significant growth of 99.5% year-on-year, with an earnings per share (EPS) of 0.789 yuan [3]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with no false records or misleading statements [2][3] - The financial report for the third quarter of 2025 has not been audited [3][5] - The net profit attributable to the parent company's shareholders, after deducting the impact of share-based payments, is 140,748,079.80 yuan [3][4] Financial Data - The company reported a loss of 8,321,702.80 yuan due to share-based payments for the period from January to September 2025 [3] - There are no non-recurring profit and loss items applicable for the reporting period [4] - The company has not reclassified any non-recurring profit and loss items as recurring [4] Shareholder Information - The company has experienced changes in the number of shareholders and their holdings, but specific details are not applicable for this report [4] - There are no changes in the top ten shareholders due to securities lending activities [4] Other Important Matters - No other significant matters are reported for the quarter [4]

Core Insights - Beijing Baipusais Biotechnology Co., Ltd. reported a significant increase in revenue and net profit for the first three quarters of 2025, with revenue reaching 613 million yuan, a year-on-year growth of 32.26%, and net profit attributable to shareholders amounting to 132 million yuan, a year-on-year increase of 58.61% [1] - In the third quarter alone, the company achieved revenue of 226 million yuan, reflecting a year-on-year growth of 37.50%, and a net profit of 48.62 million yuan, which is an impressive year-on-year increase of 81.46% [1] Financial Performance - Total revenue for the first three quarters of 2025: 613 million yuan, up 32.26% year-on-year [1] - Net profit for the first three quarters: 132 million yuan, up 58.61% year-on-year [1] - Third quarter revenue: 226 million yuan, up 37.50% year-on-year [1] - Third quarter net profit: 48.62 million yuan, up 81.46% year-on-year [1] Strategic Initiatives - The company announced plans to initiate the issuance of H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy, expand overseas business, and improve overall competitiveness [1] - The board of directors has authorized the management to start the preparatory work for the H-share issuance and listing [1]

Core Points - Beijing Baipusi Biotechnology Co., Ltd. (stock abbreviation: Baipusi, stock code: 301080) announced on October 29, 2025, that it held its second strategic committee meeting and the 22nd meeting of the second board of directors on October 28, 2025, where it approved the proposal to authorize the management to initiate the preparatory work for the overseas issuance of shares (H-shares) and listing on the Hong Kong Stock Exchange [1] - The purpose of the H-share issuance and listing is to further implement the internationalization strategy, enhance overseas business layout, broaden domestic and foreign merger and acquisition and financing channels, and improve the company's international visibility and overall competitiveness [1] - As of now, specific details regarding the proposed share issuance ratio and the appointment of intermediaries have not been determined, and the finalized plan will need to be submitted for approval by the company's board of directors and shareholders, as well as obtain the necessary filings, approvals, or authorizations from regulatory bodies such as the China Securities Regulatory Commission and the Hong Kong Stock Exchange, indicating uncertainty in the approval and implementation process [1]

Group 1 - The core point of the article is that Baipusais (SZ 301080) announced the convening of its second board meeting on October 28, 2025, to review the proposal for the Q3 2025 report [1] - For the year 2024, Baipusais' revenue composition is 98.13% from research and experimental development and 1.87% from other businesses [1] - As of the report date, Baipusais has a market capitalization of 10.8 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation [1] - The article suggests that a "slow bull" market pattern is emerging [1]

北京百普赛斯生物科技股份有限公司 章程 二〇二五年十月 | | | | | | 北京百普赛斯生物科技股份有限公司章程 第一章 总则 公司以发起方式设立，由北京百普赛斯生物科技有限公司整体变更设 立为股份有限公司，在北京经济技术开发区市场监督管理局注册登记 并取得营业执照，公司统一社会信用代码为 911103025604366893。 1 第一条 为维护北京百普赛斯生物科技股份有限公司(以下简称"公司")、公 司股东和债权人的合法权益，规范公司的组织和行为，根据《中华人 民共和国公司法》(以下简称"《公司法》")、《中华人民共和国证券 法》(以下简称"《证券法》") 、《深圳证券交易所创业板股票上市 规则》和其他有关规定，制订本章程。 第二条 公司系依照《公司法》、《证券法》和其他有关规定成立的股份有限公 司。 第三条 公司于 2021 年 4 月 16 日经深圳证券交易所审核并于 2021 年 8 月 31 日经中国证券监督管理委员会(以下简称"中国证监会")同意注册， 首次向社会公众发行人民币普通股 2,000 万股，于 2021 年 10 月 18 日 在深圳证券交易所上市。 第四条 公司注册名称：北京百 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-073 北京百普赛斯生物科技股份有限公司 关于 2025 年第三季度计提资产减值损失和信用减值损失的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 （1）金融工具减值 本公司对于以摊余成本计量的金融资产、以公允价值计量且其变动计入其他 综合收益的债权投资、合同资产、租赁应收款、贷款承诺及财务担保合同等，以 一、计提资产减值损失及信用减值损失情况概述 1、本次计提资产减值损失及信用减值损失的原因 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及北京百普赛 斯生物科技股份有限公司（以下简称"公司"或"本公司"）会计政策的相关规 定，为更加真实、准确地反映公司截至 2025 年 9 月 30 日的财务状况和经营成果， 基于谨慎性原则，公司对合并报表范围内的各类资产进行了全面清查，并进行了 充分的分析和评估，对可能发生减值损失的资产计提了减值准备。 2、资产减值损失及信用减值损失的计提情况 本次计提信用减值损失和资产 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-069 公司于 2025 年 10 月 28 日召开了第二届董事会第二十二次会议，审议通过 了《关于变更部分回购股份用途并注销的议案》，公司拟将回购专用证券账户中 第一期回购的部分股份用途由"用于员工持股计划或股权激励"变更为"用于注 销并相应减少注册资本"，该议案尚需提交公司股东会审议。此外，公司拟为回 购专用证券账户中的第二期回购股份 612,700 股办理注销手续。具体内容详见公 司同日在巨潮资讯网披露的《关于变更部分回购股份用途并注销的公告》（公告 编号：2025-068）。公司回购专用证券账户股份注销完成后，公司总股本将由 167,848,198 股变更为 167,177,695 股，注册资本将由人民币 167,848,198 元减少 至人民币 167,177,695 元，据此公司将修订《公司章程》中的相应条款。 二、《公司章程》修订情况 基于前述注册资本变更情况，公司拟对《公司章程》相应条款进行修订如下： 北京百普赛斯生物科技股份有限公司 关于减少注册资本暨修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-071 北京百普赛斯生物科技股份有限公司 关于聘请公司发行 H 股股票并在香港联合交易所有限公司上市 审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第二届董事会第二十二次会议，审议通过了《关于聘请公司发行 H 股股票并在香港联合交易所有限公司上市审计机构的议案》，同意公司聘请容诚 （香港）会计师事务所有限公司（以下简称"容诚香港"）为公司发行 H 股股 票并在香港联合交易所有限公司挂牌上市（以下简称"本次 H 股发行上市"） 的审计机构。本议案尚需提交公司股东会审议，现将相关情况公告如下： 一、拟聘会计师事务所事项的情况说明 鉴于容诚香港在境外发行上市项目方面拥有丰富的财务审计经验，具备足够 的专业能力及独立性，诚信状况良好，能够满足公司本次 H 股发行上市项目的 财务审计需求，根据公司本次 H 股发行上市工作的需要，公司拟聘请容诚香港 为本次 H 股发行上市的审计机构，为公司出具本次 H ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-070 为进一步推动国际化战略落地，加强海外业务布局，拓宽海内外并购和融资 渠道，提高公司国际知名度，提高公司整体竞争力，根据公司总体发展战略及运 营需要，公司拟在境外发行股份（H 股）并在香港联合交易所有限公司（以下简 称"香港联交所"）上市（以下简称"本次 H 股发行上市"）。公司董事会同 意授权公司管理层启动本次 H 股发行上市的相关前期筹备工作。 截至目前，本次 H 股发行上市的相关细节尚未确定。根据《深圳证券交易 所创业板股票上市规则》《境内企业境外发行证券和上市管理试行办法》等法律、 法规和规范性文件的要求，待确定具体方案后，本次 H 股发行上市尚需提交公 司董事会和股东会审议，并需取得中国证券监督管理委员会和香港联交所等相关 政府机构、监管机构备案、批准或核准。本次 H 股发行上市能否通过审议、备 案和审核批准程序并最终实施具有不确定性。 公司将依据相关法律、法规、规范性文件的规定，根据本次 H 股发行上市 申请的后续进展情况及时履行信息披露义务。公司指定信息披露媒体为《中国证 券报》《上海证券报》《证券时报》及巨潮资讯网（www. ...